These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
116 related items for PubMed ID: 20588058
1. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H. Kidney Blood Press Res; 2010; 33(3):213-20. PubMed ID: 20588058 [Abstract] [Full Text] [Related]
2. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV, Dass EE. Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [Abstract] [Full Text] [Related]
7. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M. Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665 [Abstract] [Full Text] [Related]
9. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K. Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367 [Abstract] [Full Text] [Related]
12. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S. J Int Med Res; 2005 Nov; 33(6):677-86. PubMed ID: 16372586 [Abstract] [Full Text] [Related]
15. Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy. Jo F, Morimoto S, Nakahigashi M, Kusabe M, Someya K, Morita T, Jo H, Imada T, Kosaki A, Toyoda N, Nishikawa M, Iwasaka T. Kidney Blood Press Res; 2011 Nov; 34(6):418-23. PubMed ID: 21709422 [Abstract] [Full Text] [Related]
18. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Nishimura T, Hashimoto J, Ohkubo T, Kikuya M, Metoki H, Asayama K, Totsune K, Imai Y. Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340 [Abstract] [Full Text] [Related]
19. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B. Kidney Blood Press Res; 2012 Aug; 36(1):119-30. PubMed ID: 23171828 [Abstract] [Full Text] [Related]